[1]CurrentPatentAssignee:ELILILLY&CO;PFIZERINC-WO2018/81417,2018,A2
[2]CurrentPatentAssignee:ELILILLY&CO-WO2019/84285,2019,A1
[1]CurrentPatentAssignee:ELILILLY&CO;PFIZERINC-WO2018/81417,2018,A2Locationinpatent:Page/Pagecolumn194;195;196;197
[2]CurrentPatentAssignee:ELILILLY&CO-WO2019/84285,2019,A1Locationinpatent:Page/Pagecolumn233;234
[1]CurrentPatentAssignee:ELILILLY&CO;PFIZERINC-WO2018/81417,2018,A2Locationinpatent:Page/Pagecolumn188;189
[1]CurrentPatentAssignee:ELILILLY&CO;PFIZERINC-WO2018/81417,2018,A2Locationinpatent:Page/Pagecolumn189;190;191;192;193
[1]CurrentPatentAssignee:ELILILLY&CO;PFIZERINC-WO2018/81417,2018,A2Locationinpatent:Page/Pagecolumn197;198;199;200;201
[2]CurrentPatentAssignee:ELILILLY&CO-WO2019/84285,2019,A1Locationinpatent:Page/Pagecolumn236;237
Title: Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972.